All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What do HCPs need to know about neonatal lupus?

Featured
Dec 12, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in neonatal lupus and its management.

During the 13th European Lupus Meeting, the Lupus Hub was pleased to speak to Jill Buyon, New York University, New York, US. We asked, What do healthcare professionals need to know about neonatal lupus?

What do HCPs need to know about neonatal lupus?

Jill Buyon opens by discussing the incidence of anti-Ro and anti-La antibodies in pregnancy and the likelihood of this resulting in neonatal lupus, with a focus on congenital heart block as an indicator. Buyon goes on to outline the importance of early detection and tailored treatment plans depending on the nature of the cardiovascular presentation and concludes by highlighting the potential for future at-home monitoring techniques.